Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally.
Neuland Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹1,734.50|
|52 Week High||₹975.00|
|52 Week Low||₹2,840.00|
|1 Month Change||7.23%|
|3 Month Change||-17.99%|
|1 Year Change||41.82%|
|3 Year Change||207.40%|
|5 Year Change||79.75%|
|Change since IPO||2,182.24%|
Recent News & Updates
|524558||IN Pharmaceuticals||IN Market|
Return vs Industry: 524558 exceeded the Indian Pharmaceuticals industry which returned 23.5% over the past year.
Return vs Market: 524558 underperformed the Indian Market which returned 68.3% over the past year.
Stable Share Price: 524558 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 524558's weekly volatility (7%) has been stable over the past year.
About the Company
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial and anti-parkinson, anti-ulcerants, and prostaglandins. It also provides custom manufacturing solutions, as well as peptide synthesis services.
Neuland Laboratories Fundamentals Summary
|524558 fundamental statistics|
Is 524558 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|524558 income statement (TTM)|
|Cost of Revenue||₹5.53b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||57.84|
|Net Profit Margin||7.96%|
How did 524558 perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Is Neuland Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 524558 (₹1734.5) is trading above our estimate of fair value (₹1098.4)
Significantly Below Fair Value: 524558 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 524558 is poor value based on its PE Ratio (30x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: 524558 is poor value based on its PE Ratio (30x) compared to the Indian market (22.2x).
Price to Earnings Growth Ratio
PEG Ratio: 524558 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: 524558 is good value based on its PB Ratio (2.8x) compared to the IN Pharmaceuticals industry average (3.2x).
How is Neuland Laboratories forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 524558's forecast earnings growth (20.2% per year) is above the savings rate (6.7%).
Earnings vs Market: 524558's earnings (20.2% per year) are forecast to grow faster than the Indian market (19.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 524558's revenue (12.8% per year) is forecast to grow slower than the Indian market (12.9% per year).
High Growth Revenue: 524558's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 524558's Return on Equity is forecast to be high in 3 years time
How has Neuland Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524558 has high quality earnings.
Growing Profit Margin: 524558's current net profit margins (8%) are higher than last year (3.3%).
Past Earnings Growth Analysis
Earnings Trend: 524558's earnings have grown significantly by 25.2% per year over the past 5 years.
Accelerating Growth: 524558's earnings growth over the past year (189.1%) exceeds its 5-year average (25.2% per year).
Earnings vs Industry: 524558 earnings growth over the past year (189.1%) exceeded the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 524558's Return on Equity (9.4%) is considered low.
How is Neuland Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 524558's short term assets (₹5.5B) exceed its short term liabilities (₹3.7B).
Long Term Liabilities: 524558's short term assets (₹5.5B) exceed its long term liabilities (₹1.7B).
Debt to Equity History and Analysis
Debt Level: 524558's debt to equity ratio (23.2%) is considered satisfactory.
Reducing Debt: 524558's debt to equity ratio has reduced from 66.6% to 23.2% over the past 5 years.
Debt Coverage: 524558's debt is well covered by operating cash flow (103.9%).
Interest Coverage: 524558's interest payments on its debt are well covered by EBIT (11.4x coverage).
What is Neuland Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 524558's dividend (0.35%) is higher than the bottom 25% of dividend payers in the Indian market (0.33%).
High Dividend: 524558's dividend (0.35%) is low compared to the top 25% of dividend payers in the Indian market (1.35%).
Stability and Growth of Payments
Stable Dividend: 524558 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 524558's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (8.6%), 524558's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Davuluri Rao (46 yo)
Mr. Davuluri Sucheth Rao has been the Chief Executive Officer of Neuland Laboratories Limited since August 1, 2013, where Mr. Rao also served as its Chief Operating Officer. At Neuland, Sucheth has been re...
CEO Compensation Analysis
Compensation vs Market: Davuluri's total compensation ($USD458.03K) is above average for companies of similar size in the Indian market ($USD193.06K).
Compensation vs Earnings: Davuluri's compensation has increased by more than 20% in the past year.
Experienced Management: 524558's management team is seasoned and experienced (8.2 years average tenure).
Experienced Board: 524558's board of directors are considered experienced (9.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neuland Laboratories Limited's employee growth, exchange listings and data sources
- Name: Neuland Laboratories Limited
- Ticker: 524558
- Exchange: BSE
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹22.253b
- Shares outstanding: 12.83m
- Website: https://www.neulandlabs.com
Number of Employees
- Neuland Laboratories Limited
- Phoenix IVY Building
- 11th Floor, 5th Office Level
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:07|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.